Elevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice

Kalavathi Dasuri, Jennifer K. Pepping, Sun OK Fernandez-Kim, Sunita Gupta, Jeffrey N. Keller, Philipp E. Scherer, Annadora J. Bruce-Keller

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

HIV protease inhibitors are key components of HIV antiretroviral therapies, which are fundamental in the treatment of HIV infection. However, the protease inhibitors are well-known to induce metabolic dysfunction which can in turn escalate the complications of HIV, including HIV associated neurocognitive disorders. As experimental and epidemiological data support a therapeutic role for adiponectin in both metabolic and neurologic homeostasis, this study was designed to determine if increased adiponectin could prevent the detrimental effects of protease inhibitors in mice. Adult male wild type (WT) and adiponectin-overexpressing (ADTg) mice were thus subjected to a 4-week regimen of lopinavir/ritonavir, followed by comprehensive metabolic, neurobehavioral, and neurochemical analyses. Data show that lopinavir/ritonavir-induced lipodystrophy, hypoadiponectinemia, hyperglycemia, hyperinsulinemia, and hypertriglyceridemia were attenuated in ADTg mice. Furthermore, cognitive function and blood-brain barrier integrity were preserved, while loss of cerebrovascular markers and white matter injury were prevented in ADTg mice. Finally, lopinavir/ritonavir caused significant increases in expression of markers of brain inflammation and decreases in synaptic markers in WT, but not in ADTg mice. Collectively, these data reinforce the pathophysiologic link from metabolic dysfunction to loss of cerebrovascular and cognitive homeostasis; and suggest that preservation and/or replacement of adiponectin could prevent these key aspects of HIV protease inhibitor-induced toxicity in clinical settings.

Original languageEnglish (US)
Pages (from-to)1228-1235
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1862
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

HIV Protease Inhibitors
Adiponectin
Lopinavir
Ritonavir
Homeostasis
HIV
Protease Inhibitors
Lipodystrophy
Hypertriglyceridemia
Hyperinsulinism
Encephalitis
Blood-Brain Barrier
Hyperglycemia
Cognition
Nervous System
HIV Infections
Mouse Adipoq protein
Wounds and Injuries
Therapeutics

Keywords

  • Blood-brain barrier
  • HIV antiretroviral therapy
  • HIV-associated neurocognitive disorder
  • Lipodystrophy
  • Metabolic syndrome

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Elevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice. / Dasuri, Kalavathi; Pepping, Jennifer K.; Fernandez-Kim, Sun OK; Gupta, Sunita; Keller, Jeffrey N.; Scherer, Philipp E.; Bruce-Keller, Annadora J.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1862, No. 6, 01.06.2016, p. 1228-1235.

Research output: Contribution to journalArticle

Dasuri, Kalavathi ; Pepping, Jennifer K. ; Fernandez-Kim, Sun OK ; Gupta, Sunita ; Keller, Jeffrey N. ; Scherer, Philipp E. ; Bruce-Keller, Annadora J. / Elevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2016 ; Vol. 1862, No. 6. pp. 1228-1235.
@article{9fdc39cbca254b2bbfa230fe5a8cfa85,
title = "Elevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice",
abstract = "HIV protease inhibitors are key components of HIV antiretroviral therapies, which are fundamental in the treatment of HIV infection. However, the protease inhibitors are well-known to induce metabolic dysfunction which can in turn escalate the complications of HIV, including HIV associated neurocognitive disorders. As experimental and epidemiological data support a therapeutic role for adiponectin in both metabolic and neurologic homeostasis, this study was designed to determine if increased adiponectin could prevent the detrimental effects of protease inhibitors in mice. Adult male wild type (WT) and adiponectin-overexpressing (ADTg) mice were thus subjected to a 4-week regimen of lopinavir/ritonavir, followed by comprehensive metabolic, neurobehavioral, and neurochemical analyses. Data show that lopinavir/ritonavir-induced lipodystrophy, hypoadiponectinemia, hyperglycemia, hyperinsulinemia, and hypertriglyceridemia were attenuated in ADTg mice. Furthermore, cognitive function and blood-brain barrier integrity were preserved, while loss of cerebrovascular markers and white matter injury were prevented in ADTg mice. Finally, lopinavir/ritonavir caused significant increases in expression of markers of brain inflammation and decreases in synaptic markers in WT, but not in ADTg mice. Collectively, these data reinforce the pathophysiologic link from metabolic dysfunction to loss of cerebrovascular and cognitive homeostasis; and suggest that preservation and/or replacement of adiponectin could prevent these key aspects of HIV protease inhibitor-induced toxicity in clinical settings.",
keywords = "Blood-brain barrier, HIV antiretroviral therapy, HIV-associated neurocognitive disorder, Lipodystrophy, Metabolic syndrome",
author = "Kalavathi Dasuri and Pepping, {Jennifer K.} and Fernandez-Kim, {Sun OK} and Sunita Gupta and Keller, {Jeffrey N.} and Scherer, {Philipp E.} and Bruce-Keller, {Annadora J.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.bbadis.2016.02.009",
language = "English (US)",
volume = "1862",
pages = "1228--1235",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Elevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice

AU - Dasuri, Kalavathi

AU - Pepping, Jennifer K.

AU - Fernandez-Kim, Sun OK

AU - Gupta, Sunita

AU - Keller, Jeffrey N.

AU - Scherer, Philipp E.

AU - Bruce-Keller, Annadora J.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - HIV protease inhibitors are key components of HIV antiretroviral therapies, which are fundamental in the treatment of HIV infection. However, the protease inhibitors are well-known to induce metabolic dysfunction which can in turn escalate the complications of HIV, including HIV associated neurocognitive disorders. As experimental and epidemiological data support a therapeutic role for adiponectin in both metabolic and neurologic homeostasis, this study was designed to determine if increased adiponectin could prevent the detrimental effects of protease inhibitors in mice. Adult male wild type (WT) and adiponectin-overexpressing (ADTg) mice were thus subjected to a 4-week regimen of lopinavir/ritonavir, followed by comprehensive metabolic, neurobehavioral, and neurochemical analyses. Data show that lopinavir/ritonavir-induced lipodystrophy, hypoadiponectinemia, hyperglycemia, hyperinsulinemia, and hypertriglyceridemia were attenuated in ADTg mice. Furthermore, cognitive function and blood-brain barrier integrity were preserved, while loss of cerebrovascular markers and white matter injury were prevented in ADTg mice. Finally, lopinavir/ritonavir caused significant increases in expression of markers of brain inflammation and decreases in synaptic markers in WT, but not in ADTg mice. Collectively, these data reinforce the pathophysiologic link from metabolic dysfunction to loss of cerebrovascular and cognitive homeostasis; and suggest that preservation and/or replacement of adiponectin could prevent these key aspects of HIV protease inhibitor-induced toxicity in clinical settings.

AB - HIV protease inhibitors are key components of HIV antiretroviral therapies, which are fundamental in the treatment of HIV infection. However, the protease inhibitors are well-known to induce metabolic dysfunction which can in turn escalate the complications of HIV, including HIV associated neurocognitive disorders. As experimental and epidemiological data support a therapeutic role for adiponectin in both metabolic and neurologic homeostasis, this study was designed to determine if increased adiponectin could prevent the detrimental effects of protease inhibitors in mice. Adult male wild type (WT) and adiponectin-overexpressing (ADTg) mice were thus subjected to a 4-week regimen of lopinavir/ritonavir, followed by comprehensive metabolic, neurobehavioral, and neurochemical analyses. Data show that lopinavir/ritonavir-induced lipodystrophy, hypoadiponectinemia, hyperglycemia, hyperinsulinemia, and hypertriglyceridemia were attenuated in ADTg mice. Furthermore, cognitive function and blood-brain barrier integrity were preserved, while loss of cerebrovascular markers and white matter injury were prevented in ADTg mice. Finally, lopinavir/ritonavir caused significant increases in expression of markers of brain inflammation and decreases in synaptic markers in WT, but not in ADTg mice. Collectively, these data reinforce the pathophysiologic link from metabolic dysfunction to loss of cerebrovascular and cognitive homeostasis; and suggest that preservation and/or replacement of adiponectin could prevent these key aspects of HIV protease inhibitor-induced toxicity in clinical settings.

KW - Blood-brain barrier

KW - HIV antiretroviral therapy

KW - HIV-associated neurocognitive disorder

KW - Lipodystrophy

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84962868658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962868658&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2016.02.009

DO - 10.1016/j.bbadis.2016.02.009

M3 - Article

C2 - 26912411

AN - SCOPUS:84962868658

VL - 1862

SP - 1228

EP - 1235

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 6

ER -